Literature DB >> 7724835

The rodent carcinogenicity bioassay produces a similar frequency of tumor increases and decreases: implications for risk assessment.

T S Davies1, A Monro.   

Abstract

We examined the overall results of 124 consecutive rodent carcinogenesis assays carried out at the maximum tolerated dose on 37 chemicals reported recently by the Toxicology Program of the United States. In 31 experiments each in male and female F-344 rats and in male and female B6C3F1 mice, tumor increases and decreases occurred in 41 and 46% of the experiments, respectively. In 22 experiments both increases and decreases in tumor incidence were reported. Of the experiments with decreases in tumor incidence, about 70% were associated with lower body weights of the treated animals. However, of the 30 chemicals producing some tumor decreases, 12 showed decreases in some experiments without any association with bodyweight. Ten chemicals that were Salmonella positive produced increases and decreases in tumor incidences and three produced only decreases in tumor incidence. If it is considered that the bioassay provides information relevant to the carcinogenic potential of a chemical, then logically it must also be considered that information about the cancer-preventive potential of a chemical is provided. When a chemical causes increases and decreases in tumors, several questions follow. First, which are more relevant to the health of an exposed individual: tumor increases or tumor decreases? Second, should such a chemical be stigmatized as a "carcinogen," in view of all the legal and economic implications that ensue from such a label? Third, how should one define a carcinogen?

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7724835     DOI: 10.1006/rtph.1994.1077

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  4 in total

Review 1.  Evaluation of the carcinogenic potential of pharmaceuticals. Opportunities arising from the International Conference on Harmonisation.

Authors:  A M Monro; J S MacDonald
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

Review 2.  Goodbye to the bioassay.

Authors:  Jay I Goodman
Journal:  Toxicol Res (Camb)       Date:  2018-02-06       Impact factor: 3.524

3.  Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

4.  Meta-analysis of rat lung tumors from lifetime inhalation of diesel exhaust.

Authors:  P A Valberg; E A Crouch
Journal:  Environ Health Perspect       Date:  1999-09       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.